Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ovid Therapeutics
Biotech
Ovid sells some royalty rights to Takeda-partnered seizure drug
Ovid Therapeutics has sold off part of the royalty rights to its Takeda-partnered seizure med in order to fund its operations into 2026.
James Waldron
Oct 18, 2023 8:00am
Ovid snaps up Rock2 inhibitor from Sam Waksal-led Graviton
May 1, 2023 11:06am
Former Roche pharma head to be new Bayer CEO—Chutes & Ladders
Feb 10, 2023 9:30am
Layoff 'wave' not letting up amid oversaturation of biotechs
Mar 28, 2022 10:05am
Ovid cuts 20% of staff, refocuses on epilepsy
Mar 15, 2022 2:08pm
Ovid pens deal to offload twice-failed former lead program
Feb 8, 2022 9:10am